Overview
- Lilly announced agreements on May 26, 2026 to acquire Curevo, LimmaTech Biologics and Vaccine Company in deals that together could total about $3.83 billion.
- Each deal is structured as an upfront cash payment plus milestone payments with Curevo valued up to $1.5 billion, LimmaTech up to $780 million and Vaccine Company up to $1.55 billion.
- Curevo’s amezosvatein showed Phase 2 data that matched immune responses to the standard vaccine while cutting some side effects by more than half, LimmaTech’s lead LTB‑SA7 is in Phase 1 as a Staphylococcus aureus vaccine, and Vaccine Company has a Phase 1‑ready five‑antigen EBV candidate using in vivo nanoparticle technology.
- All transactions remain subject to customary closing steps, including the Hart‑Scott‑Rodino antitrust waiting period, and the candidates face normal clinical, regulatory and commercial risks.
- Lilly said strong cash flow from its GLP‑1 diabetes and obesity drugs funds the deals, which could broaden prevention options for infections that raise long‑term health risks and also respond to rising antibiotic resistance.